N2OFF, Inc. announced on February 25, 2026 that it will change its legal name to Nexentis Technologies Inc. and adopt the Nasdaq ticker symbol NXTS, effective February 26, 2026. The board approved the name and ticker change on January 26, 2026, and the transition will be reflected on the Nasdaq Capital Market the following day.
The rebranding follows the company’s October 20, 2025 acquisition of MitoCareX Bio Ltd., a wholly‑owned subsidiary that develops small‑molecule programs targeting the mitochondrial SLC25 carrier family using its proprietary MITOLINE™ algorithm. Nexentis will continue to manage its solar‑energy investments as a non‑core, value‑optimizing asset base while concentrating on its new computational‑biotech pipeline focused on mitochondrial biology, precision oncology, and inflammatory metabolic diseases.
Historically, N2OFF operated in agri‑food technology and reported a net loss of $6.65 million for the twelve months ended September 30, 2025, with a 20.3% decline in revenue year‑over‑year for FY2024. In Q3 2025 the company posted an operating margin of –2,057.1% and a gross margin of 0.0%, underscoring the financial challenges that prompted the strategic pivot. The shift to a biotech focus is intended to address these weaknesses by leveraging the MitoCareX platform and the broader growth prospects of the mitochondrial‑targeted therapeutics market.
Management emphasized that the rebranding will “enhance strategic clarity, improve alignment with the Company’s R&D priorities, and support engagement with partners and potential collaborators across the biotech and pharmaceutical ecosystem.” The move positions Nexentis to attract investors and partners aligned with its computational biology focus and to capitalize on the projected expansion of the cancer therapeutics market from $194.1 billion in 2024 to $344.1 billion by 2031.
The transition marks a fundamental change in Nexentis’s business model, moving from legacy agri‑food and solar assets to a high‑growth biotech platform. While the company remains in an early stage of commercialization, the rebranding signals confidence in its pipeline and a commitment to improving financial performance through a more focused, technology‑driven strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.